Short Interest in Mustang Bio, Inc. (NASDAQ:MBIO) Drops By 39.2%

Mustang Bio, Inc. (NASDAQ:MBIO) was the target of a large drop in short interest in February. As of February 27th, there was short interest totaling 133,993 shares, a drop of 39.2% from the February 12th total of 220,214 shares. Based on an average daily trading volume, of 37,451 shares, the short-interest ratio is presently 3.6 days. Currently, 1.9% of the company’s stock are sold short. Currently, 1.9% of the company’s stock are sold short. Based on an average daily trading volume, of 37,451 shares, the short-interest ratio is presently 3.6 days.

Analysts Set New Price Targets

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Mustang Bio in a research note on Thursday, January 22nd. One investment analyst has rated the stock with a Sell rating, According to MarketBeat, the stock has an average rating of “Sell”.

Institutional Investors Weigh In On Mustang Bio

An institutional investor recently bought a new position in Mustang Bio stock. DRW Securities LLC purchased a new position in Mustang Bio, Inc. (NASDAQ:MBIO) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 73,936 shares of the company’s stock, valued at approximately $73,000. DRW Securities LLC owned approximately 1.01% of Mustang Bio as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors and hedge funds own 9.95% of the company’s stock.

Mustang Bio Stock Down 0.3%

Shares of Mustang Bio stock traded down $0.00 during trading on Friday, reaching $0.94. The company’s stock had a trading volume of 27,737 shares, compared to its average volume of 39,102. Mustang Bio has a 1-year low of $0.53 and a 1-year high of $7.00. The company has a 50-day simple moving average of $0.97 and a two-hundred day simple moving average of $1.23.

About Mustang Bio

Mustang Bio, Inc is a clinical‐stage biopharmaceutical company focused on the development and commercialization of novel cell and gene therapies for oncology and rare genetic diseases. The company’s primary platform leverages chimeric antigen receptor T‐cell (CAR-T) technology to target both hematologic and solid tumor indications. In parallel, Mustang Bio is advancing a portfolio of lentiviral‐based gene therapy candidates designed to address inherited metabolic disorders with high unmet medical need.

The company’s oncology pipeline includes programs directed at B-cell malignancies and aggressive brain tumors, with lead CAR-T candidates in clinical trials for glioblastoma multiforme and various B-cell leukemias and lymphomas.